Tretiakova
Anna Tretiakova, Royersford, PA US
Patent application number | Description | Published |
---|---|---|
20100273212 | PP1 Ligands - The invention relates to phosphatase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PP1 activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands. | 10-28-2010 |
Anna Tretiakova, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20160083748 | TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF - Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (ORF) for a protein under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in a selected tissue, wherein the modified ORF is characterized by a triplet frequency of any one of Tables 3-12, 16 or 17. | 03-24-2016 |
Anna P. Tretiakova, Royersford, PA US
Patent application number | Description | Published |
---|---|---|
20090136465 | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof - The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products. | 05-28-2009 |
Anna P. Tretiakova, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20120058102 | PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript. | 03-08-2012 |
20130023033 | PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript. | 01-24-2013 |
Olga Vladimirovna Tretiakova, Novosibirsk RU
Patent application number | Description | Published |
---|---|---|
20150291542 | Antiviral Water-Soluble Product with Anti-HIV Effect, Based on Ionic Silver and Methylene Blue Compound; Method of Its Production and Examples of HIV-infected Patients' Treatment - A new antiviral water-soluble pharmacological product with anti-HIV effect, is based on ionic silver and methylene blue compound. The new substance is produced in the form of water-soluble powder that can be used for the preparation of finished dosage forms for treating viral infections, especially HIV infection. The product has a potential ability to radically suppress the infectious agents without leading to any mutations and resistance of viruses. The composition of the new product proposed under the conventional name Argothiazin-A™ corresponds to the chemical formula: C | 10-15-2015 |